HFS
TRVI icon

Hughes Financial Services’s Trevi Therapeutics TRVI Stock Holding History

Hughes Financial Services’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75 Buy
4
+1
+33% +$15 ﹤0.01% 1516
2026
Q1 		$36 Buy
+3
New +$34 ﹤0.01% 1524

Other funds holding TRVI

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
PP
PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return
HCA
Harbour Capital Advisors Tysons Corner, Virginia $549M AUM 54.99% 1-Year Est. Return
DACS
Dymon Asia Capital (Singapore) Singapore $2.39B AUM 150.5% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return

Hughes Financial Services's TRVI Position: Q2 2026 in Review

Hughes Financial Services increased its Trevi Therapeutics (TRVI) stake by 33% in Q2 2026, buying an estimated $15 and bringing the position to 4 shares worth $75. The position accounts for ﹤0.01% of the portfolio, ranked #1516.

Hughes Financial Services first reported a position in TRVI in Q1 2026 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Hughes Financial Services held 4 shares of Trevi Therapeutics worth $75 as of Q2 2026.
  • Hughes Financial Services bought 1 Trevi Therapeutics share in Q2 2026, an estimated $15.
  • Trevi Therapeutics made up ﹤0.01% of Hughes Financial Services's portfolio in Q2 2026, its #1516 holding.
  • Hughes Financial Services first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Hughes Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.